# Copper-Catalyzed Intramolecular Dehydrogenative Amidation of Unactivated C(sp<sup>3</sup>)–H Bonds Using O<sub>2</sub> as the Sole Oxidant

Chunxia Wang, Yudong Yang,\* Dekun Qin, Zhen He, and Jingsong You\*

Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, and State Key Laboratory of Biotherapy, West China Medical School, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P. R. China

## **Supporting Information**

**ABSTRACT:** In this work, an aerobic copper-catalyzed intramolecular  $C(sp^3)$ -H amidation has been disclosed, which presents a rare example of copper-catalyzed functionalization of an unactivated  $C(sp^3)$ -H bond with O<sub>2</sub> as the sole oxidant. In addition, a new protocol for the preparation of a removable 5methoxyquinolyl moiety has been documented.



Recently, transition-metal-catalyzed C–H bond activation has emerged as a highly efficient strategy for selective functionalization of targeted molecules and construction of synthetically enabling structures.<sup>1</sup> Notably, transition-metalcatalyzed C-H/X-H (X = C, N, O) dehydrogenative crosscoupling reaction with O2 as the sole oxidant is regarded as an ideal approach to facilely assemble carbon-carbon bonds and carbon-heteroatom bonds due to its high atom-economy, efficiency, and environmental friendliness.<sup>2</sup> Although significant progress has been achieved in transition-metal-catalyzed aerobic oxidative functionalization of  $C(sp^2)$ -H bonds over the past decade,<sup>2b-h</sup> the analogous transformations of unactivated  $C(sp^3)$ -H bonds with air or  $O_2$  as the oxidant are still scarce. To our knowledge, only aerobic palladium-catalyzed olefinatio $n^{3a}$  and oxygenation<sup>3b</sup> of inert  $C(sp^3)$ -H bonds have been achieved with the assistance of a redox cocatalyst by Sanford and co-workers.

Lactams are important structural features that exist in a range of pharmaceuticals, agrochemicals, and natural products. Recently, tremendous efforts have been devoted to the synthesis of these compounds via transition-metal-catalyzed intramolecular amidation of inert  $C(sp^3)$ -H bonds and/or  $C(sp^2)$ -H bonds.<sup>4,5</sup> Although these approaches are concise and efficient, they generally require the use of excess amounts of oxidants such as  $Ag_2CO_3$ , BQ, PhI(OAc)<sub>2</sub>, and TEMPO, which render these processes less appealing due to the increased cost and formation of stoichiometric undesired byproducts. Considering that the different oxidation states of copper (Cu(I), Cu(II), and Cu(III)) could be mutually converted with the assistance of  $O_{22}^{6,7}$  we reasoned that copper would enable aerobic catalytic  $\bar{C(sp^3)}-H$ amidation reaction. In this work, we disclose a Cu-catalyzed intramolecular dehydrogenative amidation of unactivated C- $(sp^3)$ -H bonds with O<sub>2</sub> as the sole oxidant (Scheme 1). It should be noted that transition-metal-catalyzed functionalization of inert  $C(sp^3)$ -H bonds using  $O_2$  as the sole oxidant is still underrepresented.

We commenced our study with *N*-(quinolin-8-yl)pivalamide as the model substrate (Table 1). Gratifyingly,  $\beta$ -lactam 2a was obtained in 11% isolated yield in the presence of CuI (20 mol %) and  $Na_2CO_3$  (2.0 equiv) at 140 °C under 1 atm of  $O_2$  (entry 1). Encouraged by this result, we next investigated the bases. However, other bases, such as K<sub>2</sub>CO<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, K<sub>3</sub>PO<sub>4</sub>, CsF, and LiO<sup>t</sup>Bu, were proved to be ineffective for this reaction (entries 2-6). Interestingly, although most solvents failed to give the desired product in our tests (entries 7-11), benzonitrile was identified as a superior solvent (entry 12). Further investigation of the copper catalyst precursors revealed that the reaction was highly influenced by the nature of the copper source, and the highest yield was achieved with CuI (entries 12-17). Finally, 92% yield of 2a could be afforded when the reaction was performed in a mixture of benzonitrile and *o*-xylene (3/2) at 140  $^{\circ}$ C under 1 atm of O<sub>2</sub> for 34 h (entry 21). In addition, the yield of 2a was dramatically decreased to 36% when the reaction was carried out under an air atmosphere (entry 22). No product 2a was detected when other directing groups were employed under the optimized condition (II-IV). It should be mentioned that only trace amounts of 2a were obtained when amide 1a was subjected to the modified conditions of Ge, Kuninobu, and Kanai,  $5^{c,d}$  in which  $O_2$  was used as the sole oxidant instead.

With the optimized condition in hand, we next investigated the substrate scope of this reaction (Table 2). As expected, a variety of aliphatic amides were converted into the corresponding  $\beta$ -lactams in good to excellent yields. A preference for amidation of  $C(sp^3)$ -H bonds of the  $\beta$ -methyl groups over  $\gamma$ - and  $\delta$ -methyl groups was observed (**2b**-**d**), indicating that the formation of five-membered ring intermediates is more favorable in the cyclometalation step. In addition, this reaction showed a site-selectivity on the  $\beta$ -methyl groups over the methylene groups even in the existence of a  $\beta$ -benzylic site (**2b** and **2d**-**n**). This result is distinctly different from the previous reports on copper-catalyzed  $C(sp^3)$ -H amidation, in which a preference for the  $\beta$ -benzylic C-H was observed.

**Received:** June 9, 2015 **Published:** August 6, 2015





Table 1. Optimization of the Reaction Conditions<sup>a</sup>



entry	catalyst	base	solvent	yield <sup>®</sup> (%)
1	CuI	Na <sub>2</sub> CO <sub>3</sub>	o-xylene	11
2	CuI	K <sub>2</sub> CO <sub>3</sub>	o-xylene	trace
3	CuI	$Cs_2CO_3$	o-xylene	n. d.
4	CuI	K <sub>3</sub> PO <sub>4</sub>	o-xylene	n. d.
5	CuI	CsF	o-xylene	n. d.
6	CuI	Li <sup>t</sup> OBu	o-xylene	trace
7	CuI	Na <sub>2</sub> CO <sub>3</sub>	DCE	trace
8	CuI	Na <sub>2</sub> CO <sub>3</sub>	DMF	n. d.
9	CuI	Na <sub>2</sub> CO <sub>3</sub>	NMP	n. d.
10	CuI	Na <sub>2</sub> CO <sub>3</sub>	1,2-dioxane	trace
11	CuI	Na <sub>2</sub> CO <sub>3</sub>	CH <sub>3</sub> CN	trace
12	CuI	Na <sub>2</sub> CO <sub>3</sub>	PhCN	41
13	CuCl	Na <sub>2</sub> CO <sub>3</sub>	PhCN	11
14	CuBr	Na <sub>2</sub> CO <sub>3</sub>	PhCN	17
15	Cu <sub>2</sub> O	Na <sub>2</sub> CO <sub>3</sub>	PhCN	trace
16	$Cu(acac)_2$	Na <sub>2</sub> CO <sub>3</sub>	PhCN	trace
17	$Cu(OAc)_2$	Na <sub>2</sub> CO <sub>3</sub>	PhCN	trace
18	CuI	Na <sub>2</sub> CO <sub>3</sub>	PhCN/o-xylene (2/3)	52
19	CuI	Na <sub>2</sub> CO <sub>3</sub>	PhCN/o-xylene (3/2)	72
20	CuI	Na <sub>2</sub> CO <sub>3</sub>	PhCN/o-xylene (4/1)	66
21 <sup>c</sup>	CuI	Na <sub>2</sub> CO <sub>3</sub>	PhCN/o-xylene (3/2)	92
$22^d$	CuI	Na <sub>2</sub> CO <sub>3</sub>	PhCN/o-xylene (3/2)	36

<sup>*a*</sup>General conditions: **1a** (0.25 mmol), catalyst (20 mol %), and base (2.0 equiv) were stirred in solvent (0.5 mL) at 140 °C for 24 h under an atmosphere of  $O_2$ . <sup>*b*</sup>Isolated yields. <sup>*c*</sup>Stirred at 140 °C for 34 h. <sup>*d*</sup>Air instead of  $O_2$ . n. d. = not detected.

cyclic chains were used as substrates, both the  $\beta$ -methyl and the methylene amidated products were obtained, with a slight preference for the spiro-products (20–q). Furthermore, 2-phenyl-substituted propanamide was also suitable for the

reaction condition and exclusively gave the methyl  $C(sp^3)$ -H amidated product in good yield (2r).

To further understand the mechanism, 2,6-di-*tert*-butyl-*p*-cresol (BHT), which is known as a radical inhibitor, was added. It

Table 2. Investigation of Substrate Scope $^{a,b}$ 



<sup>*a*</sup>Reaction conditions: 1 (0.25 mmol), CuI (20 mol %), and Na<sub>2</sub>CO<sub>3</sub> (2.0 equiv) were stirred in PhCN/o-xylene (0.3 mL/0.2 mL) at 140 °C for 34 h under an O<sub>2</sub> atmosphere. <sup>*b*</sup>Isolated yields. <sup>*c*</sup>Stirred at 170 °C for 34 h. <sup>*d*</sup>CuCl instead of CuI was used, 34 h, 170 °C.

was observed that BHT could significantly suppress this reaction, and no product 2a was detected in the presence of 2.0 equiv of BHT (Scheme 2), thus indicating that a radical process may be involved in this transformation.

On the basis of the above observations as well as previous reports,  $^{5d,6,7}$  a plausible mechanism is shown in Scheme 3. Initially, Cu(I) reacts with O<sub>2</sub> to afford a Cu(II)-superoxide radical, which undergoes electron transfer oxidation and H-abstraction to produce a Cu(II)-hydroperoxo species.<sup>6a</sup> Next, the resulting Cu(II) species coordinates with amide 1 to form the





*N*,*N*-chelated copper complex **A**. Next, the C(sp<sup>3</sup>)–H cupration delivers the cyclometallic intermediate **B**, followed by a disproportionation process to generate Cu(III) complex **C**. It should be mentioned that the possibility of direct oxidation of Cu(II) complex **B** to Cu(III) species **C** by O<sub>2</sub> could not be ruled out at this stage.<sup>2d,7a</sup> Finally, reductive elimination of the complex **C** releases the  $\beta$ -lactam **2** and Cu(I) species to accomplish the catalytic cycle.

Removal of the quinolyl moiety is a key step to give free  $\beta$ lactams. However, the current methods generally need the use of the 5-methoxy analogue, which requires a multiple synthetic procedure to access.<sup>5a</sup> Inspired by the transition-metal-catalyzed  $C(sp^2)$ -H methoxylation,<sup>8</sup> we found that free  $\beta$ -lactams could be feasibly afforded by sequential nickel-catalyzed methoxylation, copper-catalyzed amidation, and oxidative cleavage, which significantly shortened the synthetic route (Scheme 4).

To conclude, a copper-catalyzed intramolecular amidation of an unactivated  $C(sp^3)$ —H bond of aliphatic acid derivatives using  $O_2$  as the sole oxidant has been reported. Compared with previously reported transition-metal-catalyzed amidation reactions, the aerobic oxidative functionalization of  $C(sp^3)$ —H bonds

## Scheme 3. Proposed Mechanism



Scheme 4. Synthesis of Free  $\beta$ -Lactams



developed herein provides a more economical and practical approach to diverse  $\beta$ -lactams.

## EXPERIMENTAL SECTION

**General Information.** The <sup>1</sup>H NMR (400 MHz) chemical shifts were measured using CDCl<sub>3</sub> or TMS as the internal reference (CDCl<sub>3</sub>:  $\delta$  = 7.26 ppm, TMS:  $\delta$  = 0.00 ppm). The <sup>13</sup>C NMR (100 MHz) chemical shifts are given using CDCl<sub>3</sub> as the internal standard (CDCl<sub>3</sub>:  $\delta$  = 77.16 ppm). High-resolution mass spectra (HR-MS) were obtained with a Q-TOF (ESI). Compounds **1a–1r** were prepared according to the literature procedure.<sup>5</sup>

**2,2,4-Trimethyl-***N***-(quinolin-8-yl)pentanamide (1d).** Compound **1d**, pale yellow oil (5.41 g, 67%), was prepared from methyl isobutyrate (3.06 g, 30 mmol) and 1-iodo-2-methylpropane (8.28 g, 45 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.89 (d, *J* = 6.8 Hz, 6H), 1.41 (s, 6H), 1.69 (d, *J* = 6.4 Hz, 2H), 1.73–1.81 (m, 1H), 7.43 (dd, *J* = 8.4 Hz, 4.4 Hz, 1H), 7.45–7.54 (m, 2H), 8.13 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.79–8.82 (m, 2H), 10.28 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 24.1, 25.4, 26.5, 43.6, 50.4, 116.2, 121.2, 121.6, 127.5, 128.0, 134.7, 136.4, 138.8, 148.3, 177.0 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 271.1810, found 271.1810.

**2,2-Dimethyl-***N***-(quinolin-8-yl)hexanamide (1f).** Compound 1f, pale yellow oil (3.89 g, 48%), was prepared from methyl isobutyrate (3.06 g, 30 mmol) and 1-iodobutane (8.28 g, 45 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.88 (t, *J* = 6.8 Hz, 3H), 1.31–1.34 (m, 4H), 1.40 (s,

6H), 1.69–1.73 (m, 2H), 7.43 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 7.46–7.54 (m, 2H), 8.13 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.80 (d, J = 1.6 Hz, 1H), 8.82 (dd, J = 3.2 Hz, 1.6 Hz, 1H), 10.25 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 14.1, 23.4, 25.8, 27.2, 41.5, 43.9, 116.3, 121.3, 121.6, 127.5, 128.0, 134.8, 136.4, 138.9, 148.3, 176.9 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 271.1810, found 271.1812.$ 

**2,2-Dimethyl-***N***-(quinolin-8-yl)pentanamide (1g).** Compound **1g**, pale yellow oil (2.48 g, 32%), was prepared from methyl isobutyrate (3.06 g, 30 mmol) and 1-iodopropane (7.65 g, 45 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.91 (t, *J* = 7.2 Hz, 3H), 1.32–1.41 (m, 8H), 1.66–1.70 (m, 2H), 7.40 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.43–7.53 (m, 2H), 8.10 (dd, *J* = 8.0 Hz, 1.6 Hz, 1H), 8.79–8.82 (m, 2H), 10.25 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.7, 18.3, 25.7, 43.9, 44.0, 116.2, 121.2, 121.6, 127.5, 127.9, 134.7, 136.3, 138.8, 148.3, 176.8 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>16</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 257.1654, found 257.1653.

**2-Methyl-2-propyl-***N***-(quinolin-8-yl)hexanamide (1h).** Compound **1h**, pale yellow oil (0.85 g, 29%), was prepared from 2-methylpentanoic acid (1.16 g, 10 mmol) and 1-iodobutane (2.76 g, 15 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.88 (t, *J* = 6.8 Hz, 3H), 0.92 (t, *J* = 7.2 Hz, 3H), 1.24–1.37 (m, 5H), 1.38 (s, 3H), 1.40–1.46 (m, 1H), 1.52–1.62 (m, 2H), 1.77–1.87 (m, 2H), 7.45 (dd, *J* = 8.4 Hz, 4.4 Hz, 1H), 7.47–7.55 (m, 2H), 8.15 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.80–8.83 (m, 2H), 10.23 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.1, 14.8, 18.0, 21.4, 23.5, 26.9, 40.4, 43.0, 47.5, 116.3, 121.2, 121.6, 127.6, 128.1, 134.8, 136.4, 139.0, 148.3, 176.4 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>19</sub>H<sub>27</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 299.2123, found 299.2125.

**2,2-Dimethyl-3-trifluoromethyl-***N*-(quinolin-8-yl)propanamide (1i). Compound 1i, yellow oil (0.92 g, 31%), was prepared from methyl isobutyrate (1.02 g, 10 mmol) and 2-iodo-1,1,1-trifluoroethane (4.20 g, 20 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 1.58$  (d, J = 0.8 Hz, 6H), 2.65 (q, J = 11.2 Hz, 2H), 7.47 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 7.51–7.57 (m, 2H), 8.17 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.78 (dd, J = 6.4 Hz, 2.4 Hz, 1H), 8.82(dd, J = 4.4 Hz, 1.6 Hz, 1H), 10.38 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 20.8$ , 25.8, 41.30–41.33 (m), 43.0 (q, J = 28 Hz), 116.5, 121.8, 121.9, 126.5 (q, J = 276 Hz), 127.5, 128.1, 134.4, 136.5, 138.9, 148.5, 174.2 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>15</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 297.1215, found 297.1217.

**2,2-Dimethyl-***N*-(**quinolin-8-yl**)-**3**-(**3-thienyl**)**propanamide** (**1n**). Compound **1n**, yellow solid (7.24 g, 78%), was prepared from methyl isobutyrate (3.06 g, 30 mmol) and 3-bromomethylthiophene (7.97 g, 45 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.42 (s, 6H), 3.07 (s, 2H), 6.92 (dd, *J* = 4.8 Hz, 1.2 Hz, 1H), 7.01 (d, *J* = 1.6 Hz, 1H), 7.13 (dd, *J* = 4.8 Hz, 3.2 Hz, 1H), 7.44 (dd, *J* = 8.4 Hz, 4.4 Hz, 1H), 7.49–7.57 (m, 2H), 8.15 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.77 (dd, *J* = 4.4 Hz, 1.6 Hz, 1H), 8.83 (dd, *J* = 7.6 Hz, 1.6 Hz, 1H), 10.19 (s, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 25.6, 41.5, 44.9, 116.4, 121.5, 121.7, 123.0, 125.0, 127.6, 128.1, 129.7, 134.7, 136.4, 138.4, 138.9, 148.3, 176.2 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>18</sub>H<sub>19</sub>N<sub>2</sub>OS [M + H]<sup>+</sup> 311.1218, found 311.1218.

General Procedure for Copper-Catalyzed  $C(sp^3)$ –H Amidation. Amide 1 (0.25 mmol), CuI (9.5 mg, 0.05 mmol), Na<sub>2</sub>CO<sub>3</sub> (53.0 mg, 0.5 mmol), and PhCN/o-xylene (0.5 mL, 3/2) were added into an oven-dried 35 mL Schlenk tube with a magnetic stir bar under an O<sub>2</sub> atmosphere. Then, the vial was sealed and stirred rigorously at 140 °C for 34 h. After removal of the solvent, the residue was purified by chromatography on silica gel (petroleum ether/EtOAc, 10/1) to give the desired product 2.

**3,3-Dimethyl-1-(quinolin-8-yl)azetidin-2-one (2a).**<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a colorless oil (52.0 mg, 92%).

**3-Ethyl-3-methyl-1-(quinolin-8-yl)azetidin-2-one (2b).**<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (48.1 mg, 80%).

**3-IsopropyI-3-methyI-1-(quinolin-8-yI)azetidin-2-one (2c).** Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (59.8 mg, 94%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 1.04$  (d, J = 6.8 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.41 (s, 3H), 2.03–2.10 (m, 1H), 4.17 (d, J = 7.2 Hz, 1H), 4.39 (d, J = 7.2 Hz, 1H), 7.36 (dd, J = 8.4 Hz, 4.0 Hz, 1H), 7.45–7.50 (m, 2H), 8.08 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.49 (dd, J = 5.6 Hz, 3.2 Hz, 1H), 8.80 (dd, J = 4.4 Hz, 2.0 Hz, 1H) pm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 16.6$ , 17.8, 18.4, 31.9, 57.0, 59.3, 119.4, 121.2, 122.8, 126.8, 129.1, 135.1, 136.0, 140.5, 148.5, 173.5 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 277.1317, found 277.1317.

**3-Isobutyl-3-methyl-1-(quinolin-8-yl)azetidin-2-one (2d).** Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (65.7 mg, 98%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.97 (d, *J* = 6.4 Hz, 3H), 1.00 (d, *J* = 6.4 Hz, 3H), 1.44 (s, 3H), 1.55–1.61 (m, 1H), 1.81–1.91 (m, 2H), 4.31 (d, *J* = 7.6 Hz, 1H), 4.45 (d, *J* = 7.6 Hz, 1H), 7.37 (dd, *J* = 8.4 Hz, 4.0 Hz, 1H), 7.46–7.51 (m, 2H), 8.09 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.50 (dd, *J* = 6.4 Hz, 3.2 Hz, 1H), 8.80 (dd, *J* = 4.4 Hz, 2.0 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 19.3, 22.7, 24.4, 25.2, 43.1, 54.9, 60.1, 119.5, 121.3, 122.8, 126.9, 129.1, 135.3, 136.0, 140.5, 148.6, 174.0 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 291.1473, found 291.1469.

**3-Methyl-3-pentyl-1-(quinolin-8-yl)azetidin-2-one (2e).**<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (62.8 mg, 89%).

**3-Butyl-3-methyl-1-(quinolin-8-yl)azetidin-2-one (2f).** Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (50.3 mg, 75%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 0.92$  (t, J = 7.2 Hz, 3H), 1.34–1.41 (m, 3H), 1.44 (s, 3H), 1.48–1.60 (m, 1H), 1.73–1.77 (m, 2H), 4.25 (d, J = 7.2 Hz, 1H), 4.40 (d, J = 7.6 Hz, 1H), 7.37 (dd, J = 8.4 Hz, 4.0 Hz, 1H), 7.48–7.49 (m, 2H), 8.09 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.50 (dd, J = 5.6 Hz, 3.2 Hz, 1H), 8.80 (dd, J = 4.4 Hz, 2.0 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 14.1$ , 19.7, 23.2,

27.1, 34.8, 55.4, 58.8, 119.5, 121.3, 122.8, 126.9, 129.1, 135.2, 136.0, 140.5, 148.5, 173.6 ppm; HRMS (ESI<sup>+</sup>): calcd for  $C_{17}H_{20}N_2ONa$  [M + Na]<sup>+</sup> 291.1473, found 291.1477.

**3-Methyl-3-propyl-1-(quinolin-8-yl)azetidin-2-one (2g).** Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (47.1 mg, 74%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.97 (t, *J* = 7.2 Hz, 3H), 1.39–1.48 (m, 4H), 1.54–1.63 (m, 1H), 1.71–1.75 (m, 2H), 4.25 (d, *J* = 7.2 Hz, 1H), 4.41 (d, *J* = 7.2 Hz, 1H), 7.37 (dd, *J* = 8.4 Hz, 4.4 Hz, 1H), 7.46–7.51 (m, 2H), 8.09 (dd, *J* = 8.0 Hz, 1.6 Hz, 1H), 8.49 (dd, *J* = 6.0 Hz, 3.2 Hz, 1H), 8.80 (dd, *J* = 4.0 Hz, 1.6 Hz, 1H) pm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.6, 18.3, 19.7, 37.3, 55.5, 58.8, 119.5, 121.3, 122.8, 126.9, 129.1, 135.2, 136.0, 140.5, 148.5, 173.6 pm; HRMS (ESI<sup>+</sup>): calcd for C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 277.1317, found 277.1315.

**3-Butyl-3-propyl-1-(quinolin-8-yl)azetidin-2-one (2h).** Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (59.3 mg, 80%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 0.92 (t, *J* = 6.8 Hz, 3H), 0.97 (t, *J* = 7.2 Hz, 3H), 1.32–1.61 (m, 6H), 1.71–1.78 (m, 4H), 4.30–4.35 (m, 2H), 7.38 (dd, *J* = 8.4 Hz, 4.4 Hz, 1H), 7.46–7.51 (m, 2H), 8.10 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.50 (dd, *J* = 6.0 Hz, 3.2 Hz, 1H), 8.81 (dd, *J* = 4.0 Hz, 1.6 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 14.2, 14.7, 18.1, 23.4, 26.9, 33.2, 35.7, 56.5, 59.5, 119.4, 121.3, 122.7, 126.9, 129.1, 135.1, 136.0, 140.5, 148.6, 173.2 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>19</sub>H<sub>25</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 297.1967, found 297.1975.

**3-Methyl-1-(quinolin-8-yl)-3-(2,2,2-trifluoroethyl)azetidin-2-one (2i).** Purified by column chromatography (petroleum ether/ EtOAc, 10/1) as a pale yellow oil (46.3 mg, 63%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.59 (s, 3H), 2.59–2.67 (m, 2H), 4.42 (d, *J* = 8.0 Hz, 1H), 4.65 (d, *J* = 8.0 Hz, 1H), 7.39 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.47–7.56 (m, 2H), 8.11 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.44 (dd, *J* = 7.6 Hz, 1.6 Hz, 1H), 8.82 (dd, *J* = 4.0 Hz, 1.6 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 19.1, 38.1 (q, *J* = 28 Hz), 51.17–51.19 (m), 58.7, 119.9, 121.5, 123.5, 126.6 (q, *J* = 277 Hz), 126.8, 129.0, 134.7, 136.1, 140.5, 148.9, 170.3 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>15</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 317.0878, found 317.0873.

**3-(4-Methoxybenzyl)-3-methyl-1-(quinolin-8-yl)azetidin-2one (2j).**<sup>5c</sup> Purified by column chromatography (petroleum ether/ EtOAc, 10/1) as a pale yellow oil (69.8 mg, 84%).

**3-(3,5-Dimethylbenzyl)-3-methyl-1-(quinolin-8-yl)azetidin-2-one (2k).** Purified by column chromatography (petroleum ether/ EtOAc, 10/1) as a pale yellow oil (54.5 mg, 66%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.46 (s, 3H), 2.29 (s, 6H), 2.89 (d, *J* = 14.0 Hz, 1H), 3.14 (d, *J* = 14.0 Hz, 1H), 4.32 (d, *J* = 7.2 Hz, 1H), 4.41 (d, *J* = 7.6 Hz, 1H), 6.85 (s, 1H), 6.92 (s, 2H), 7.36 (dd, *J* = 8.4 Hz, 4.4 Hz, 1H), 7.48–7.51 (m, 2H), 8.08 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.44 (dd, *J* = 6.4 Hz, 2.8 Hz, 1H), 8.79 (dd, *J* = 4.4 Hz, 2.0 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.0, 21.4, 40.7, 56.0, 58.1, 119.8, 121.3, 123.0, 126.8, 127.9, 128.3, 129.0, 135.0, 136.0, 137.3, 137.8, 140.6, 148.6, 173.3 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 353.1630, found 353.1633.

**3-Methyl-3-(3-methylbenzyl)-1-(quinolin-8-yl)azetidin-2one (2l).** Purified by column chromatography (petroleum ether/ EtOAc, 10/1) as a pale yellow oil (47.5 mg, 60%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.45 (s, 3H), 2.33 (s, 3H), 2.92 (d, *J* = 13.6 Hz, 1H), 3.16 (d, *J* = 14.0 Hz, 1H), 4.31 (d, *J* = 7.6 Hz, 1H), 4.42 (d, *J* = 7.2 Hz, 1H), 7.02 (d, *J* = 7.2 Hz, 1H), 7.09–7.11 (m, 2H), 7.18 (t, *J* = 7.6 Hz, 1H), 7.36 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.45–7.51 (m, 2H), 8.08 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 8.42 (dd, *J* = 6.4 Hz, 2.4 Hz, 1H), 8.78 (dd, *J* = 4.0 Hz, 2.0 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.0, 21.6, 40.8, 56.0, 58.1, 119.8, 121.3, 123.0, 126.8, 127.1, 127.5, 128.3, 129.1, 130.9, 135.0, 136.0, 137.4, 138.0, 140.6, 148.6, 173.1 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 339.1473, found 339.1480.

**3-(4-Bromobenzyl)-3-methyl-1-(quinolin-8-yl)azetidin-2-one** (**2m**). <sup>5c</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (45.8 mg, 48%).

**3-Methyl-1-(quinolin-8-yl)-3-(thiophen-3-ylmethyl)azetidin-2-one (2n).** Purified by column chromatography (petroleum ether/ EtOAc, 10/1) as a pale yellow oil (41.6 mg, 54%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.47 (s, 3H), 3.03 (d, *J* = 14.4 Hz, 1H), 3.18 (d, *J* = 14.4 Hz, 1H), 4.32 (d, *J* = 7.2 Hz, 1H), 4.39 (d, *J* = 7.2 Hz, 1H), 7.07 (dd, *J* = 4.8 Hz, 1.2 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 7.24 (dd, J = 4.8 Hz, 2.8 Hz, 1H), 7.36 (dd, J = 8.4 Hz, 4.0 Hz, 1H), 7.45–7.52 (m, 2H), 8.08 (dd, J = 8.4 Hz, 2.0 Hz, 1H), 8.42 (dd, J = 6.8 Hz, 2.4 Hz, 1H), 8.78 (dd, J = 4.0 Hz, 1.6 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 19.9$ , 35.4, 55.8, 58.1, 119.7, 121.3, 122.9, 123.1, 125.5, 126.8, 129.0, 129.3, 134.9, 136.0, 137.6, 140.5, 148.6, 172.9 ppm; HRMS (ESI<sup>+</sup>): calcd for C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>OSNa [M + Na]<sup>+</sup> 331.0881, found 331.0883.

**2-(Quinolin-8-yl)-2-azaspiro[3.4]octan-1-one** (20).<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (22.1 mg, 35%).

**1-Methyl-6-(quinolin-8-yl)-6-azabicyclo[3.2.0]heptan-7-one** (**20'**).<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (21.4 mg, 34%).

**2-(Quinolin-8-yl)-2-azaspiro[3.5]nonan-1-one (2p)**.<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (26.6 mg, 40%).

**1-Methyl-7-(quinolin-8-yl)-7-azabicyclo[4.2.0]octan-8-one** (**2p**'). Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (12.7 mg, 19%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 1.36-1.43$  (m, 2H), 1.45 (s, 3H), 1.50-1.57 (m, 1H), 1.61-1.73 (m, 2H), 1.82-1.98 (m, 3H), 4.99 (t, J = 3.6 Hz, 1H), 7.39 (dd, J = 8.4 Hz, 4.4 Hz, 1H), 7.49-7.57 (m, 2H), 8.11 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H), 8.39 (dd, J = 7.2 Hz, J = 1.6 Hz, 1H), 8.84 (dd, J = 4.0 Hz, J = 1.6 Hz, 1H) pm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 16.0$ , 18.4, 21.3, 23.6, 27.9, 53.3, 64.0, 121.3, 123.7, 127.0, 129.2, 134.4, 136.1, 140.7, 148.9, 173.6 pm; HRMS (ESI<sup>+</sup>): calcd for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>ONa [M + Na]<sup>+</sup> 289.1317, found 289.1320.

**2-(Quinolin-8-yl)-2-azaspiro[3.6]decan-1-one (2q).**<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (37.1 mg, 53%).

**1-Methyl-8-(quinolin-8-yl)-8-azabicyclo[5.2.0]nonan-9-one** (**2q'**). <sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (14.7 mg, 21%).

**3-Methyl-3-phenyl-1-(quinolin-8-yl)azetidin-2-one (2r).**<sup>5d</sup> Purified by column chromatography (petroleum ether/EtOAc, 10/1) as a pale yellow oil (44.7 mg, 62%).

**1-(5-Methoxyquinolin-8-yl)-3,3-dimethylazetidin-2-one (4a).**<sup>54</sup> Purified by column chromatography (petroleum ether/EtOAc, 8/1) as a pale yellow oil (44.2 mg, 69%).

Synthesis of Compound 3a. Amide 1a (0.25 mmol), Ni $(\text{acac})_2$  (6.4 mg, 0.05 mmol), PhI $(OMe)_2$  (133.0 mg, 0.5 mmol), PPh<sub>3</sub> (13.1 mg, 0.05 mmol), and MeOH (2 mL) were added into an oven-dried 50 mL Schlenk tube with a magnetic stir bar under an air atmosphere. Then, the vial was sealed and stirred rigorously at 140 °C for 24 h. After removal of the solvent, the residue was purified by chromatography on silica gel (2% EtOAc in petroleum ether, v/v) to afford the desired product 3a in 52% (33.6 mg) yield as a slightly yellow solid.<sup>5d</sup>

Effect of Radical Scavenger BHT on Copper-Catalyzed  $C(sp^3)$ -H Amidation. Amide 1 (0.25 mmol), CuI (9.5 mg, 0.05 mmol), Na<sub>2</sub>CO<sub>3</sub> (53.0 mg, 0.5 mmol), BHT (110.2 mg, 0.5 mmol), and PhCN/*o*-xylene (0.5 mL, 3/2) were added into an oven-dried 35 mL Schlenk tube with a magnetic stir bar under an O<sub>2</sub> atmosphere. Then, the vial was sealed and stirred rigorously at 140 °C for 24 h. Upon completion, no desired product was detected.

# ASSOCIATED CONTENT

#### **Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.Sb01302.

Copies of <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of the products (PDF)

# AUTHOR INFORMATION

#### **Corresponding Authors**

\*E-mail: jsyou@scu.edu.cn (J.Y.).

\*E-mail: yangyudong@scu.edu.cn (Y.Y.).

## Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENTS

We thank the National NSF of China for the financial support (Nos. 21272160, 21432005, and 21321061).

## REFERENCES

(1) For selected reviews on transition-metal-catalyzed C-H bond activation, see: (a) Daugulis, O.; Do, H.-Q.; Shabashov, D. Acc. Chem. Res. 2009, 42, 1074. (b) Giri, R.; Shi, B.-F.; Engle, K. M.; Maugel, N.; Yu, J.-Q. Chem. Soc. Rev. 2009, 38, 3242. (c) Jazzar, R.; Hitce, J.; Renaudat, A.; Sofack-Kreutzer, J.; Baudoin, O. Chem. - Eur. J. 2010, 16, 2654. (d) Baudoin, O. Chem. Soc. Rev. 2011, 40, 4902. (e) Yeung, C. S.; Dong, V. M. Chem. Rev. 2011, 111, 1215. (f) Ackermann, L. Chem. Rev. 2011, 111, 1315. (g) Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. Angew. Chem., Int. Ed. 2012, 51, 8960. (h) Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. Angew. Chem., Int. Ed. 2012, 51, 10236.

(2) For selected examples of transition-metal-catalyzed C-H dehydrogenative functionalization with O<sub>2</sub> as the sole oxidant, see: (a) Hamada, T.; Ye, X.; Stahl, S. S. J. Am. Chem. Soc. **2008**, 130, 833. (b) Monguchi, D.; Fujiwara, T.; Furukawa, H.; Mori, A. Org. Lett. **2009**, 11, 1607. (c) Xiao, B.; Gong, T.-J.; Liu, Z.-J.; Liu, J.-H.; Luo, D.-F.; Xu, J.; Liu, L. J. Am. Chem. Soc. **2011**, 133, 9250. (d) John, A.; Nicholas, K. M. J. Org. Chem. **2011**, 76, 4158. (e) Zhu, C.; Yi, M.; Wei, D.; Chen, X.; Wu, Y.; Cui, X. Org. Lett. **2014**, 16, 1840. (f) Xu, H.; Qiao, X.; Yang, S.; Shen, Z. J. Org. Chem. **2014**, 79, 4414. (g) Li, G.; Jia, C.; Chen, Q.; Sun, K.; Zhao, F.; Wu, H.; Wang, Z.; Lv, Y.; Chen, X. Adv. Synth. Catal. **2015**, 357, 1311. (h) Lu, Y.; Wang, H.-W.; Spangler, J. E.; Chen, K.; Cui, P.-P.; Zhao, Y.; Sun, W.-Y.; Yu, J.-Q. Chem. Sci. **2015**, 6, 1923.

(3) (a) Stowers, K. J.; Fortner, K. C.; Sanford, M. S. *J. Am. Chem. Soc.* **2011**, 133, 6541. (b) Stowers, K. J.; Kubota, A.; Sanford, M. S. *Chem. Sci.* **2012**, 3, 3192.

(4) Zhang, Q.; Chen, K.; Shi, B.-F. Synlett 2014, 25, 1941.

(5) For selected examples of transition-metal-catalyzed intramolecular dehydrogenative amidation of inert C-H bonds, see: (a) He, G.; Zhang, S.-Y.; Nack, W. A.; Li, Q.; Chen, G. Angew. Chem., Int. Ed. **2013**, *52*, 11124. (b) Zhang, Q.; Chen, K.; Rao, W.; Zhang, Y.; Chen, F.-J.; Shi, B.-F. Angew. Chem., Int. Ed. **2013**, *52*, 13588. (c) Wang, Z.; Ni, J.; Kuninobu, Y.; Kanai, M. Angew. Chem., Int. Ed. **2014**, *53*, 3496. (d) Wu, X.; Zhao, Y.; Zhang, G.; Ge, H. Angew. Chem., Int. Ed. **2014**, *53*, 3706. (e) Wu, X.; Zhao, Y.; Ge, H. Chem. - Eur. J. **2014**, *20*, 9530. (f) Sun, W.-W.; Cao, P.; Mei, R.-Q.; Li, Y.; Ma, Y.-L.; Wu, B. Org. Lett. **2014**, *16*, 480. (g) Wu, X.; Yang, K.; Zhao, Y.; Sun, H.; Li, G.; Ge, H. Nat. Commun. **2015**, *6*, 6462.

(6) (a) Mirica, L. M.; Ottenwaelder, X.; Stack, T. D. P. Chem. Rev. 2004, 104, 1013. (b) Wendlandt, A. E.; Suess, A. M.; Stahl, S. S. Angew. Chem., Int. Ed. 2011, 50, 11062. (c) Guo, X.-X.; Gu, D.-W.; Wu, Z.; Zhang, W. Chem. Rev. 2015, 115, 1622.

(7) (a) Chiba, S.; Zhang, L.; Lee, J.-Y. J. Am. Chem. Soc. 2010, 132, 7266. (b) Hoover, J. M.; Ryland, B. L.; Stahl, S. S. J. Am. Chem. Soc. 2013, 135, 2357. (c) Zhang, L.-B.; Hao, X.-Q.; Zhang, S.-K.; Liu, K.; Ren, B.; Gong, J.-F.; Niu, J.-L.; Song, M.-P. J. Org. Chem. 2014, 79, 10399. (d) Huo, C.; Wang, C.; Wu, M.; Jia, X.; Xie, H.; Yuan, Y. Adv. Synth. Catal. 2014, 356, 411.

(8) For selected examples of transition-metal-catalyzed  $C(sp^2)$ -H methoxylation, see: (a) Desai, L. V.; Malik, H. A.; Sanford, M. S. Org. Lett. **2006**, 8, 1141. (b) Wang, G.-W.; Yuan, T.-T. J. Org. Chem. **2010**, 75, 476. (c) Suess, A. M.; Ertem, M. Z.; Cramer, C. J.; Stahl, S. S. J. Am. Chem. Soc. **2013**, 135, 9797.